It was anything but a quiet August for healthcare M&A. Chris Wilson, a partner at Goodwin’s private equity group and co-chair of the healthcare practice, described a “tale of two cities.” Read The Deal article here.
Related Content
- Client SpotlightApril 22, 2026
1x1 With Dr. Jessica Gaulton at FamilyWell
- AlertMarch 24, 2026
FTC Launches Healthcare Task Force, Signaling Heightened Antitrust and Consumer Protection Enforcement
- AlertMarch 23, 2026
Ninth Circuit Enables 340B False Claims Act Enforcement
- AlertMarch 5, 2026
Fifth Circuit Adopts Narrow Interpretation of Two Critical DEA Regulations
- InsightFebruary 17, 2026
Antitrust & Competition Healthcare Year in Review 2025
- AlertFebruary 13, 2026
Express Scripts Settles PBM FTC Action and Must Make Fundamental Changes to PBM Model
- AlertFebruary 11, 2026
OIG’s Latest Guidance Targets Medicare Advantage Fraud
- Health HeadlinesJanuary 30, 2026
Health Headlines: January 2026
- WebinarApril 22, 2026
Digital Health Startup Survival Guide: FDA, HIPAA, AI & Beyond
- Press ReleaseApril 16, 2026
Stereotaxis Announces Definitive Agreement to Acquire Robocath
- In the PressApril 14, 2026
Weight-Loss Drug M&A Engorges Deal Values in 2025, Driven by Fat Cheque for Metsera – Dealspeak EMEA (Mergermarket)
- In the PressApril 9, 2026
Rantum Capital Acquires German Medtech Firm Tontarra (Healthcare Business International)
- In the PressApril 1, 2026
Factors Driving Change For Medtechs And Biotechs – A Legal View (In Vivo)
- Press ReleaseMarch 31, 2026
Goodwin Advises WHOOP on $575 Million Series G Financing to Accelerate Global Health Platform Expansion
- In the PressMarch 31, 2026
As FCA Meets 340B, Geyser Of Qui Tam Suits May Erupt (Law360)
- EventsMarch 31, 2026
2026 ACG NY 18th Annual Healthcare Conference